Jefferies Financial Group Inc. Buys 29,860 Shares of Eton Pharmaceuticals, Inc. $ETON

Jefferies Financial Group Inc. boosted its holdings in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) by 33.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 118,300 shares of the company’s stock after purchasing an additional 29,860 shares during the quarter. Jefferies Financial Group Inc. owned about 0.44% of Eton Pharmaceuticals worth $2,000,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ETON. Millennium Management LLC raised its stake in Eton Pharmaceuticals by 156.3% during the 1st quarter. Millennium Management LLC now owns 355,929 shares of the company’s stock valued at $4,620,000 after purchasing an additional 217,042 shares during the period. Goldman Sachs Group Inc. raised its stake in Eton Pharmaceuticals by 34.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 175,220 shares of the company’s stock valued at $2,274,000 after purchasing an additional 45,341 shares during the period. Jane Street Group LLC raised its stake in Eton Pharmaceuticals by 49.1% during the 1st quarter. Jane Street Group LLC now owns 95,919 shares of the company’s stock valued at $1,245,000 after purchasing an additional 31,596 shares during the period. JPMorgan Chase & Co. raised its stake in Eton Pharmaceuticals by 114.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 242,580 shares of the company’s stock valued at $3,457,000 after purchasing an additional 129,467 shares during the period. Finally, Legal & General Group Plc bought a new stake in Eton Pharmaceuticals during the 2nd quarter valued at approximately $41,000. Institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Price Performance

ETON opened at $32.40 on Thursday. The business has a fifty day moving average of $26.59 and a 200 day moving average of $20.03. Eton Pharmaceuticals, Inc. has a 52-week low of $13.09 and a 52-week high of $35.66. The company has a quick ratio of 0.88, a current ratio of 1.21 and a debt-to-equity ratio of 0.62. The stock has a market cap of $887.44 million, a P/E ratio of -462.79 and a beta of 0.82.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its quarterly earnings data on Thursday, May 14th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.05). The business had revenue of $24.27 million for the quarter, compared to analysts’ expectations of $22.31 million. Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%. As a group, sell-side analysts anticipate that Eton Pharmaceuticals, Inc. will post 0.82 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on ETON shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Tuesday, April 21st. Wall Street Zen raised Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, March 21st. B. Riley Financial lifted their price objective on Eton Pharmaceuticals from $26.00 to $31.00 and gave the stock a “buy” rating in a research note on Friday, March 20th. HC Wainwright lifted their price objective on Eton Pharmaceuticals from $52.00 to $57.00 and gave the stock a “buy” rating in a research note on Friday, May 15th. Finally, Zacks Research downgraded Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 17th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Eton Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $41.00.

Insiders Place Their Bets

In other Eton Pharmaceuticals news, insider David Krempa sold 19,679 shares of Eton Pharmaceuticals stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $31.47, for a total transaction of $619,298.13. Following the completion of the sale, the insider directly owned 25,249 shares of the company’s stock, valued at $794,586.03. The trade was a 43.80% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last three months, insiders sold 100,000 shares of company stock worth $3,229,921. Insiders own 16.49% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.